ORIC Pharmaceuticals Inc.

Today we reported our Q3 2025 financial results and shared continued progress across our pipeline of promising oncology therapies as we prepare for the potential initiation of two pivotal trials in 2026. We remain focused on advancing therapies that have the potential to Overcome Resistance In Cancer and make a meaningful difference for patients. Read more here: https://bit.ly/3K24YfE

Today we announced the completion of the dose exploration portion of the Phase 1b trial of ORIC-944 in combination with AR inhibitors in patients with metastatic castration-resistant prostate cancer (mCRPC). Based on the totality of efficacy and safety data generated to date, including the new results shared today, we’ve selected our provisional recommended Phase 2 doses (RP2Ds) to advance into dose optimization. Next up: dose optimization data on the horizon for Q1 2026–stay tuned. Learn more here: https://bit.ly/4p7lhqi

Today we celebrate National STEM Day, honoring the curiosity, creativity, and collaboration that drive scientific discovery forward. At ORIC®, we’re advancing innovative therapies with the potential to Overcome Resistance In Cancer through the power of science and it all starts with inspiring the next generation of thinkers, problem-solvers, and innovators who will change the future of medicine. From the classroom to the lab, every experiment, question, and “aha!” moment brings us closer to breakthroughs that can transform lives. #NationalSTEMDay #STEMEducation #Biotech

We’re excited to announce the publication of a peer-reviewed research paper in Cancer Research, a journal of the American Association for Cancer Research. The scientific paper details preclinical data demonstrating enozertinib’s (ORIC-114) exquisite selectivity, strong potency, brain-penetrance, and anti-tumor activity across a broad range of EGFR mutant models and highlights a patient vignette in which treatment with enozertinib resulted in a sustained complete response of all systemic and brain metastases in non-small cell lung cancer (NSCLC). Learn more here: https://bit.ly/4p1ugJY

November is Lung Cancer Awareness Month, a time to honor the strength of patients, families, and caregivers affected by this devastating disease, and to reaffirm our commitment to advancing better treatment options. At ORIC®, we’re advancing the development of our EGFR/HER2 exon 20 inhibitor, enozertinib (ORIC-114), for the potential treatment of non-small cell lung cancer (NSCLC), with the goal of delivering a new treatment option to patients. Together, we can turn awareness into action and progress into impact. #LungCancerAwarenessMonth #CancerResearch

The ORIC® team was proud to join forces with the prostate cancer community at the recent ZERO Prostate Cancer Run/Walk in San Diego. From the first step at the starting line to the finish-line cheers, our team stood alongside survivors, caregivers, advocates and every person whose life has been touched by prostate cancer. Together we helped raise awareness, funds and hope. Our dedication to prostate cancer is reflected in ORIC-944, our potential best-in-class PRC2 inhibitor in development for the treatment of prostate cancer. #ZEROProstateCancer #CancerResearch

This weekend we presented two posters at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics highlighting preclinical data demonstrating the potential of ORIC-944 to treat castration sensitive prostate cancer and various other solid tumors. These data underscore the potential of ORIC-944 to overcome resistance, not only in prostate cancer but also across other solid tumors. Read more here: https://bit.ly/3L8cHZW

October marks Breast Cancer Awareness Month, a time to honor the strength of patients, survivors, and families, and to reflect on the urgent need for continued progress in cancer research and treatment. At ORIC®, our “why” is to Overcome Resistance In Cancer, one of the greatest challenges in treatment today. By advancing science, we aim to bring new hope and lasting impact to people living with breast cancer and beyond. #BreastCancerAwareness #CancerResearch #MyWhyLBBC

The ORIC® team was proud to join the 2025 GO2 San Francisco Bay Area 5K Walk/Run. This event unites lung cancer survivors, caregivers, and supporters to raise awareness and funds for patient support and research with the goal to accelerate potential cures. Our dedication to the continued development of our EGFR/HER2 inhibitor, enozertinib (ORIC-114) for the potential treatment of non-small cell lung cancer is fueled by the voices, stories, and resilience of those affected by this disease. #GO2forLungCancer #LungCancerAwareness #CancerResearch 

On #WorldCancerResearchDay, we honor the scientists, physicians, and patients driving progress against cancer. At ORIC®, we are advancing our portfolio of innovative investigational oncology therapies to potentially Overcome Resistance In Cancer and deliver better outcomes for patients. Learn more: https://bit.ly/3Wd6EnK #CancerResearch #WCRD